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HIV-1 CRF07_BC
Infections,
Injecting Drug
Users, Taiwan 
To the Editor: To date, Taiwan’s
human immunodeficiency virus type
1 (HIV-1) epidemic has primarily
spread via sexual contact. The sub-
type B and circulating recombinant
form (CRF) 01_AE account for >95%
of all infections (1). However, since
2003 Taiwan has experienced a major
outbreak of CRF07_BC among inject-
ing drug users (IDUs).
The first wave of HIV-1 infections
in Taiwan can be traced to the early
1980s, when a group of hemophilia
patients received imported HIV-1-
contaminated antihemophilia medica-
tions. By the time these medications
had been replaced by heat-treated fac-
tor VIII concentrates, at least 53
patients had contracted HIV-1 infec-
tions (2). According to Taiwan’s
Center for Disease Control (CDC),
HIV infections have been diagnosed
in 9,229 persons (including 523 for-
eigners) as of July 31, 2005 (3). The
number of persons living with HIV-
1/AIDS has increased rapidly in the
past few years, with a 77% increase in
2004, compared to 11% in 2003
(online Table, available at http://
www.cdc.gov/ncidod/EID/vol12no04
/05-0762.htm#table). According to
the results of a risk factor analysis of
people living with HIV-1/AIDS
reported to the Taiwan CDC, the pro-
portion of IDUs increased from 1.7%
(13/773) in 2002 to 8.1% (70/861) in
2003 to 30.3% (462/1,521) in 2004
(online Table). The Taiwan CDC
received reports of 1,241 IDUs diag-
nosed with HIV-1 infections from
January 1 to July 31, 2005; these
account for >75% of all reported HIV-
1 infections in 2005 (3). The evidence
points to an explosive epidemic of
HIV-1 infections among IDUs in
Taiwan since 2003, with no indication
of a slowdown.
Taiwan has ≈60,000 IDUs (1).
According to the Republic of China
Ministry of Justice, the number of
incarcerated drug offenders increased
from 5,988 in 2003 to 9,303 in 2004;
the rate of HIV-1 seropositive inmates
increased from 13.3/100,000 in 2002
to 56.8/100,000 in 2004 (Y-M. Wu,
Ministry of Justice, pers. comm.).
Since all inmates are routinely tested
for HIV-1 in detention centers, and all
infected inmates are separated from
HIV-1–seronegative inmates, the
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potential of HIV-1 transmission in
prisons is remote. We therefore sug-
gest that the Taiwanese IDU popula-
tion and its HIV-1 seropositive rate
have both increased rapidly in the past
few years.
To identify the primary HIV-1
strains in the current epidemic, we
collected blood specimens from HIV-
1-infected inmates in 3 detention cen-
ters (1 each located in the northern,
central and southern regions of
Taiwan). HIV-1 subtypes were deter-
mined by polymerase chain reaction,
DNA sequencing, and phylogenetic
analyses of pol or  env genes. Our
results indicate that 145 (96%) of 151
IDUs were infected with CRF07_BC
and 6 (4%) were infected with sub-
type B; 97% of the CRF07_BC cases
were diagnosed in 2003 or 2004.
According to our phylogenetic analy-
sis of the env gene, the Taiwanese
CRF07_BC strains clustered with
CRF07_BC strains drawn from IDUs
in China (Figure). 
CRF07_BC is a recombinant of
the B′ and C subtypes. Several studies
have suggested that CRF07_BC orig-
inated in China’s Yunnan Province,
with subtype B′ from Thailand mixing
with subtype C from India before
moving northwestward to Xinjiang
Province along a major Chinese hero-
in trafficking route (4–6). To our
knowledge, this is the first report of a
large group of IDUs in northeastern
Asia having CRF07_BC infections. It
may have followed another drug traf-
ficking route from Yunnan Province
to southeast China, moving through
Guangxi Province and Hong Kong to
Taiwan (7–9). In a bid to combat sky-
rocketing HIV/AIDS infection rates
among IDUs, the Taiwan CDC has
proposed a 5-year harm reduction
program to the Republic of China
Executive Yuan.
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Figure. Phylogenetic analyses of 7 HIV-1 isolates identified in Taiwan. TW-7496, TW-D16,
TW-D17, and TW-D22 were collected from detention center inmates; TW-9541 and TW-
9539 were collected from a blood donor and 1 of his donation recipients. This neighbor-
joining tree was created from 100 bootstrap samples of aligned env sequences correspon-
ding to the 7077–7340 nucleotide residues of HIV-1-HXB2 from different isolates.
Bootstrap values are shown on branch nodes. Reference isolates from the GenBank HIV
database are indicated by subtype.LETTERS
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Chlamydialike
Organisms and
Atherosclerosis
To the Editor: Chlamydophila
pneumoniae  causes pneumonia, but
its role in the pathogenesis of athero-
sclerosis is controversial (1–4). The
role of C. pneumoniae in atheroscle-
rosis is supported by seroepidemio-
logic studies and detection in athero-
sclerotic lesions by polymerase chain
reaction (PCR), immunohistologic
analysis, culture, and electron micro-
scopy (2,3). However, these results
were not confirmed by other serologic
or PCR-based studies (4). Meijer et al.
evaluated abdominal aortic aneurysm
biopsy specimens and detected C.
pneumoniae membrane antigen more
frequently than lipopolysaccharide
antigens but did not detect heat shock
protein 60 (1). In addition, they could
not amplify or detect specific C. pneu-
moniae  DNA by PCR and fluores-
cence in situ hybridization (1). They
hypothesized that this discrepancy
may result from a chlamydialike
organism present in aortic samples
that has surface antigens similar to
those of C. pneumoniae. 
Parachlamydia acanthamoebae
and  Neochlamydia hartmanellae are
chlamydialike organisms that share
≈86% 16S rRNA sequence similarity
with  C.  pneumoniae  (5). Like C.
pneumoniae,  they have elementary
and reticulate bodies visible by elec-
tron microscopy (6).  Neochlamydia-
related DNA (GenBank accession no.
AF097191) has been amplified from 5
different arterial samples, including 1
aortic aneurysm (7), and a relation-
ship (p = 0.009) between cerebral
hemorrhage and serologic evidence of
Parachlamydia  infection has been
reported (8). Therefore, we investigat-
ed the role of Parachlamydia  in
pathogenesis of atherosclerosis by
using a molecular approach.
We analyzed 78 surgical samples
from 27 patients undergoing aortic or
carotid surgery for atherosclerotic dis-
ease at Hôpital Nord in Marseille
from June 1, 2003, to December 31,
2003. The study was approved by the
local ethics committee, and written
informed consent was obtained from
all participants. Demographic and
clinical data were prospectively
recorded. 
DNA was extracted from aortic or
carotid samples with atherosclerotic
lesions by using the QIAamp DNA
tissue kit (Qiagen, Courtaboeuf,
France), according to the manufactur-
er’s instructions. A nested PCR was
performed by using external primers
16SIGF (5′-CGGCGTGGATGAG-
GCAT-3′) and 16SIGR (5′-TCAGTC-
CCAGTGTTGGC-3′) (9) and internal
primers CHL16SFOR2 (5′-CGTG-
GATGAGGCATGCAAGTCGA-3′)
and CHL16SREV2 (5′-CAATCTCT-
CAATCCGCCTAGACGTCTTAG-
3′) (7). PCR included negative con-
trols from the DNA extraction step.
DNA extractions and PCR amplifica-
tions were conducted in a laboratory
in which parachlamydial DNA had
not been extracted or amplified. PCR
products were purified by using the
QIAquick PCR purification kit
(Qiagen) and sequenced by using the
d-rhodamine terminator cycle
sequencing reaction kit (Perkin-Elmer
Biosystems, Warrington, UK) and a
3100 ABI Prism automated sequencer
(Applied Biosystems, Courtaboeuf,
France). 
Sequences were analyzed with
BLAST (http://www.ncbi.nlm.nih.
gov/BLAST/) using gap existence and
extension penalties of 5 and 2, respec-
tively. Results were considered posi-
tive only when the sequence of the
amplified product exhibited a best
BLAST hit with a chlamydialike
organism. Statistical analyses were
performed with STATA software
(Stata Corporation, College Station,
TX, USA).
A positive PCR result was
obtained with samples from 5 (18.5%)
of 27 patients (Table). Three
sequences had a best BLAST hit with
the sequence of Parachlamydia  sp.
UV7 (GenBank accession no.
AJ715410), with a sequence similari-
ty ranging from 99% to 100%. The
other 2 sequences had 98% sequence
similarity with Neochlamydia-related
symbiont TUME-1 (GenBank acces-
sion no. AF098330). PCR positivity
was not associated with age, sex, or
location of the atherosclerotic lesion. 
All patients with positive PCR
results were >68 years of age. Patients
without cardiovascular risk factors
were more likely than those with
>1 risk factor to have positive PCR
results (p = 0.023). Despite the small
number of patients in this study, this
association was also confirmed in a
multivariate logistic regression model
adjusted for sex and previous cardio-
vascular disease (odds ratio 0.035,
95% confidence interval 0.001–0.94). 
These findings suggest that
Parachlamydia  and  Neochlamydia
are associated with atherosclerosis. In
addition, these obligate intracellular